| Schedule of Non-Controlling Interests in Consolidated Entities |
Non-controlling interests in consolidated entities are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended |
|
|
|
|
|
|
|
|
As of March 31, 2022 |
|
March 31, 2022 |
|
As of March 31, 2022 |
|
|
|
|
|
Non-controlling interests |
|
Net loss attributable to |
|
Non-controlling interests |
|
Non-controlling |
|
($ in thousands) |
|
equity share |
|
non-controlling interests |
|
in consolidated entities |
|
ownership |
|
UR-1 |
|
$ |
423 |
|
$ |
(315) |
|
$ |
108 |
|
34.5 |
% |
Aevitas |
|
|
(5,057) |
|
|
(190) |
|
|
(5,247) |
|
45.9 |
% |
Avenue 2 |
|
|
3,286 |
|
|
(2,326) |
|
|
960 |
|
82.8 |
% |
Baergic |
|
|
(2,086) |
|
|
(90) |
|
|
(2,176) |
|
39.0 |
% |
Cellvation |
|
|
(1,544) |
|
|
(74) |
|
|
(1,618) |
|
21.7 |
% |
Checkpoint 1 |
|
|
29,839 |
|
|
(13,603) |
|
|
16,236 |
|
80.3 |
% |
Coronado SO |
|
|
(290) |
|
|
— |
|
|
(290) |
|
13.0 |
% |
Cyprium |
|
|
(2,166) |
|
|
(260) |
|
|
(2,426) |
|
29.0 |
% |
Helocyte |
|
|
(5,529) |
|
|
(110) |
|
|
(5,639) |
|
18.3 |
% |
JMC |
|
|
19,120 |
|
|
(457) |
|
|
18,663 |
|
41.6 |
% |
Mustang 2 |
|
|
95,305 |
|
|
(16,181) |
|
|
79,124 |
|
81.3 |
% |
Oncogenuity |
|
|
(1,124) |
|
|
(103) |
|
|
(1,227) |
|
24.9 |
% |
Tamid |
|
|
(740) |
|
|
(9) |
|
|
(749) |
|
22.8 |
% |
Total |
|
$ |
129,437 |
|
$ |
(33,718) |
|
$ |
95,719 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended |
|
|
|
|
|
|
|
|
As of December 31, 2021 |
|
December 31, 2021 |
|
As of December 31, 2021 |
|
|
|
|
|
Non-controlling interests |
|
Net loss attributable to |
|
Non-controlling interests |
|
Non-controlling |
|
($ in thousands) |
|
equity share |
|
non-controlling interests |
|
in consolidated entities |
|
ownership |
|
UR-1 |
|
$ |
(442) |
|
|
(1,353) |
|
$ |
(1,795) |
|
34.5 |
% |
Aevitas |
|
|
(4,159) |
|
|
(901) |
|
|
(5,060) |
|
45.9 |
% |
Avenue 2 |
|
|
5,739 |
|
|
(2,909) |
|
|
2,830 |
|
82.0 |
% |
Baergic |
|
|
(2,047) |
|
|
(39) |
|
|
(2,086) |
|
39.0 |
% |
Cellvation |
|
|
(1,413) |
|
|
(131) |
|
|
(1,544) |
|
21.7 |
% |
Checkpoint 1 |
|
|
63,464 |
|
|
(39,226) |
|
|
24,238 |
|
81.5 |
% |
Coronado SO |
|
|
(290) |
|
|
— |
|
|
(290) |
|
13.0 |
% |
Cyprium |
|
|
(1,397) |
|
|
(807) |
|
|
(2,204) |
|
29.8 |
% |
Helocyte |
|
|
(5,440) |
|
|
(89) |
|
|
(5,529) |
|
18.3 |
% |
JMC |
|
|
23,150 |
|
|
(5,652) |
|
|
17,498 |
|
41.6 |
% |
Mustang 2 |
|
|
141,527 |
|
|
(48,518) |
|
|
93,009 |
|
82.7 |
% |
Oncogenuity |
|
|
(627) |
|
|
(497) |
|
|
(1,124) |
|
24.9 |
% |
Tamid |
|
|
(739) |
|
|
(1) |
|
|
(740) |
|
22.8 |
% |
Total |
|
$ |
217,326 |
|
$ |
(100,123) |
|
$ |
117,203 |
|
|
|
Note 1: |
Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights. |
Note 2: |
Avenue and Mustang are consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Preferred Class A Shares which provide super-majority voting rights. |
|